Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,250.00
Ask: 12,700.00
Change: 0.00 (0.00%)
Spread: 450.00 (3.673%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,556.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-EU to extend COVID vaccine export controls to end of June - sources

Thu, 04th Mar 2021 11:46

(adds context)

By Francesco Guarascio and John Chalmers

BRUSSELS, March 4 (Reuters) - The European Union is planning
to extend its export authorisation scheme for COVID-19 vaccines
to the end of June, two EU sources told Reuters on Thursday, in
a move that could reignite tensions with countries who rely on
shots made in the EU.

The mechanism was set up at the end of January as a reaction
to vaccine makers' announcements of delays in the deliveries of
COVID-19 vaccines to the EU.

It is due to expire at the end of March, but the European
Commission wants to extend it through June, the two officials
said.

"The Commission will propose its extension into June. And
that was greeted by the member states with approval, not
necessarily enthusiasm, but there is a feeling that we still
need that mechanism," one senior EU diplomat said.

The second official added that at a meeting with EU
diplomats on Wednesday, many countries supported the measure,
including heavyweights Germany and France.

The EU Commission was not immediately available for a
comment.

Italian Prime Minister Mario Draghi has also called for
sanctions on companies that do not respect their contractual
obligations with the EU.

When the EU's export control mechanism was introduced in
late January it triggered an outcry from importing countries who
feared their vaccine supplies might have been hampered.

Under the scheme, companies must get an authorisation before
exporting COVID-19 shots, and may have export requests denied if
they do not respect their supply commitments with the EU.

However, the EU has authorised all requests for export since
the scheme's debut on Jan. 30 to Feb. 26, which amounted to 150
requests for millions of shots to 29 countries, including
Britain, the United Arab Emirates and Canada, an EU Commission
spokeswoman said.

She added, however, that at least one request was withdrawn
by an exporting company. She declined to elaborate.

Export requests mostly concern the Pfizer-BioNTech
vaccine which is manufactured in Belgium. AstraZeneca
and Moderna shots have also been exported from
the EU.

Since Jan. 30 more than 8 million vaccines were shipped from
the EU to Britain, a third EU source said.

Britain has so far prevented the export of AstraZeneca
vaccines to the EU, using a UK-first clause in its supply
contract with the Anglo-Swedish firm, EU officials have said.

The United States also has regulations that effectively ban
vaccine exports, the head of the European Commission Ursula von
der Leyen told a news conference last week.
(Reporting by Francesco Guarascio @fraguarascio and John
Chalmers; Editing by Toby Chopra)

More News
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.